Journal of Multiple Sclerosis and Neuroimmunology

Real-World Epidemiology of Multiple Sclerosis in Korea: Insights from a 2025 Nationwide Hospital-Based Multicenter Study: Sooyoung Kim, Ho Jin Kim, Jae-Won Hyun, Eun-Jae Lee, Young-Min Lim, Hyunjin Kim, Ju-Hong Min, Byung Joon Kim, Seung Ho Choo, Sung-Min Kim, Dong Seok Ohn, Ha Young Shin, Young Nam Kwon, Seung Woo Kim, Ki Hoon Kim, Jun Soon Kim, Woojun Kim, Tai-Seung Nam, You-Ri Kang, Min Su Park, Eunhee Sohn, Kyong Jin Shin, Byung-Jo Kim, Seol-Hee Baek, Jin-Woo Park, Sun-Young Oh, Young Eun Park, Yoon-Ho Hong, Suk-Won Ahn, Woohee Ju, Jeeyoung Oh, Hye Lim Lee, Tae-Kyeong Lee, Byeong-Jun Jeon, Nam-Hee Kim, Sunyoung Kim, Soonwook Kwon, Byeol-A Yoon, Jong Kuk Kim, Jinseok Park, Jin Myoung Seok, Jeong Bin Bong, Eun Bin Cho, Yoo Hwan Kim, Jong Seok Bae, Seong-il Oh, Sung Sang Yoon, Jiwon Yang, Do-Hyung Kim, Jee Eun Kim, Juhyeon Kim, Hyun-June Shin, Ohyun Kwon, Ahwon Kim, Sa-Yoon Kang, Jung Im Seok, Minsung Kang, Joo Hye Sung, Hung Youl Seok, Jinhong Shin, Jae-Hwan Choi, Dae-Seong Kim, Je Hong Min, In Soo Joo, Jung Min So, Su-Hyun Kim; J Mult Scler Neuroimmunol. 2025;16(2):53-59. Published online December 31, 2025; DOI: https://doi.org/10.59578/jmsni.2025.16.2.53-59; Full text PubReader ePub PDF

Disability Measurement in Multiple Sclerosis: Beyond EDSS: You-Ri Kang, Tai-Seung Nam; J Mult Scler Neuroimmunol. 2025;16(2):45-52. Published online December 31, 2025; DOI: https://doi.org/10.59578/jmsni.2025.16.2.45-52; Full text PubReader ePub PDF

Cognitive Dysfunction and Assessment in Multiple Sclerosis: Eun Oh, Seong-il Oh; J Mult Scler Neuroimmunol. 2025;16(2):35-44. Published online December 31, 2025; DOI: https://doi.org/10.59578/jmsni.2025.16.2.35-44; Full text PubReader ePub PDF

Ocrelizumab's Place in the Therapeutic Landscape at its 2019 Launch in France: Grégoire Mercier, David Pau, Guillaume Bourel, Manon Belhassen, Floriane Deygas, Clarisse Marchal, Sophie Larrieu, Alexandre Civet, Xavier Moisset; J Mult Scler Neuroimmunol. 2025;16(1):19-25. Published online June 30, 2025; DOI: https://doi.org/10.59578/jmsni.2025.16.1.19-25; Full text PubReader ePub PDF Supplementary Material

Collaboration between Medical Association and Patient Organizations to Overcome Rare Neurological Disorders: Ki Hoon Kim, Young Nam Kwon, Jun-Soon Kim, Sooyoung Kim, Seung Woo Kim, Kee Hong Park, Jin-Sung Park, Jeong Bin Bong, Jin Myoung Seok, Hung Youl Seok, Hye Lim Lee, Eunbin Cho, Byeoung-Jun Jeon, Seong-il Oh, Public Relations Committee of Korean Society for Neuroimmunology; J Mult Scler Neuroimmunol. 2025;16(1):8-18. Published online June 30, 2025; DOI: https://doi.org/10.59578/jmsni.2025.16.1.8-18; Full text PubReader ePub PDF

Summary of Cladribine (from Development to Clinical and Practical Treatment): Kyong Jin Shin; J Mult Scler Neuroimmunol. 2024;15(2):55-58. Published online December 31, 2024; DOI: https://doi.org/10.59578/jmsni.2024.15.2.55-58; Full text PubReader ePub PDF

The Clinical Utility of the Ocrelizumab for the Patients with Multiple Sclerorsis: Suk-Won Ahn; J Mult Scler Neuroimmunol. 2024;15(2):49-54. Published online December 31, 2024; DOI: https://doi.org/10.59578/jmsni.2024.15.2.49-54; Full text PubReader ePub PDF

Severe Neutropenia Following Rituximab Treatment in Patients with Multiple Sclerosis: Ki Hoon Kim, Su-Hyun Kim, Jae-Won Hyun, Ho Jin Kim; J Mult Scler Neuroimmunol. 2024;15(1):31-34. Published online June 30, 2024; DOI: https://doi.org/10.59578/jmsni.2024.15.1.31; Full text PubReader ePub PDF

Clinicoradiological Factors for Predicting and Monitoring the Progression of Multiple Sclerosis: Jiwon Yang; J Mult Scler Neuroimmunol. 2024;15(1):1-6. Published online June 30, 2024; DOI: https://doi.org/10.59578/jmsni.2024.15.1.1; Full text PubReader ePub PDF Supplementary Material

A Case of Multiple Sclerosis Presenting with Tumefactive Lesions: Yu-jin Kang, Sang-Gon Lee, Suk-Won Ahn; J Mult Scler Neuroimmunol. 2023;14(2):125-129. Published online December 31, 2023; DOI: https://doi.org/10.59578/jmsni.2023.14.2.125; Full text PubReader ePub PDF

Contemporary Patterns of High-Efficacy Disease Modifying Therapy Use in Korean Patients with Relapsing-Remitting Multiple Sclerosis: Su-Hyun Kim, Na Young Park, Min Jeong Kim, Ki Hoon Kim, Jae-Won Hyun, Ho Jin Kim; J Mult Scler Neuroimmunol. 2023;14(2):99-105. Published online December 31, 2023; DOI: https://doi.org/10.59578/jmsni.2023.14.2.99; Full text PubReader ePub PDF

Transocular Ultrasonography in Central Nervous System (CNS) Demyelinating Disease: A Narrative Review of the Clinical Utility in Optic Neuritis and CNS Demyelinating Disease: Young Nam Kwon, Sang Beom Kim; J Mult Scler Neuroimmunol. 2023;14(2):80-86. Published online December 31, 2023; DOI: https://doi.org/10.59578/jmsni.2023.14.2.80; Full text PubReader ePub PDF

A Review for Vaccination Guidelines in Patients with Central Nervous System Demyelinating Diseases including COVID-19 Vaccination: Hyun Ji Lyou, Hye Lim Lee; J Mult Scler Neuroimmunol. 2023;14(2):73-79. Published online December 31, 2023; DOI: https://doi.org/10.59578/jmsni.2023.14.2.73; Full text PubReader ePub PDF

Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study: Su-Hyun Kim, Eun-Jae Lee, Ju-Hong Min, Sung-Min Kim, Ha Young Shin, Young Nam Kwon, Woojun Kim, Jeeyoung Oh, Jun Soon Kim, Seol-Hee Baek, In Soo Joo, Yoon-Ho Hong, Min Su Park, Eunhee Sohn, Tai-Seung Nam, Sun-Young Oh, So-Young Huh, Tae-Kyeong Lee, Jiwon Yang, Sunyoung Kim, Hung Youl Seok, Nam-Hee Kim, Jin-Hong Shin, Jeong Bin Bong, Soonwook Kwon, Seong-il Oh, Eunbin Cho, Hyun-June Shin, Hyung-Soo Lee, Kee Hong Park, Woo Kyung Kim, Jong Seok Bae, Ho Jin Kim; J Mult Scler Neuroimmunol. 2023;14(1):51-55. Published online June 30, 2023; DOI: https://doi.org/10.59578/jmsni.2023.14.1.51
Cited By 4; Full text PubReader ePub PDF

Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis: Je-Young Shin, Suk-Won Ahn; J Mult Scler Neuroimmunol. 2023;14(1):9-14. Published online June 30, 2023; DOI: https://doi.org/10.59578/jmsni.2023.14.1.9; Full text PubReader ePub PDF

3,354	Autoimmune Nodopathy: When to Suspect and How to Treat?
3,019	National Consensus Guidance for Management of Refractory Myasthenia Gravis
2,111	Monoclonal Antibody Treatment for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder
1,958	Clinicoradiological Factors for Predicting and Monitoring the Progression of Multiple Sclerosis
1,520	Severe Neutropenia Following Rituximab Treatment in Patients with Multiple Sclerosis

Cited By 1	National Consensus Guidance for Management of Refractory Myasthenia Gravis
Cited By 1	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as a Diffuse Pachymeningitis

Search